CO2018008173A2 - Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) - Google Patents
Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)Info
- Publication number
- CO2018008173A2 CO2018008173A2 CONC2018/0008173A CO2018008173A CO2018008173A2 CO 2018008173 A2 CO2018008173 A2 CO 2018008173A2 CO 2018008173 A CO2018008173 A CO 2018008173A CO 2018008173 A2 CO2018008173 A2 CO 2018008173A2
- Authority
- CO
- Colombia
- Prior art keywords
- disorders
- rock
- compounds
- kinase inhibitors
- related compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula (I): (I) o estereoisómeros, tautómeros o sales del mismolos farmacéuticamente aceptables, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores de ROCK selectivos. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y a métodos para tratar trastornos cardiovasculares, trastornos relacionados con el músculo liso, trastornos oncológicos, trastornos neuropatológicos, trastornos autoinmunitarios, trastornos fibróticos y/o trastornos inflamatorios mediante su uso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662278122P | 2016-01-13 | 2016-01-13 | |
PCT/US2017/013323 WO2017123860A1 (en) | 2016-01-13 | 2017-01-13 | Spiroheptane salicylamides and related compounds as inhibitors of rock |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018008173A2 true CO2018008173A2 (es) | 2018-08-21 |
Family
ID=57907009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0008173A CO2018008173A2 (es) | 2016-01-13 | 2018-08-01 | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) |
Country Status (28)
Country | Link |
---|---|
US (2) | US10611776B2 (es) |
EP (2) | EP3402790B1 (es) |
JP (2) | JP6976953B2 (es) |
KR (1) | KR20180097749A (es) |
CN (1) | CN108699038B (es) |
AR (1) | AR107354A1 (es) |
AU (2) | AU2017206820B2 (es) |
BR (1) | BR112018013780B1 (es) |
CA (1) | CA3010900A1 (es) |
CL (1) | CL2018001899A1 (es) |
CO (1) | CO2018008173A2 (es) |
CY (1) | CY1124858T1 (es) |
EA (1) | EA036172B1 (es) |
ES (1) | ES2898698T3 (es) |
HR (1) | HRP20211888T1 (es) |
HU (1) | HUE057455T2 (es) |
IL (1) | IL260448B (es) |
LT (1) | LT3402790T (es) |
MA (2) | MA55633A (es) |
MX (2) | MX2018008219A (es) |
PL (1) | PL3402790T3 (es) |
PT (1) | PT3402790T (es) |
RS (1) | RS62690B1 (es) |
SG (1) | SG11201805927YA (es) |
SI (1) | SI3402790T1 (es) |
TW (1) | TWI730032B (es) |
UY (1) | UY37073A (es) |
WO (1) | WO2017123860A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10123993B2 (en) | 2015-01-09 | 2018-11-13 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
ES2797904T3 (es) | 2016-01-13 | 2020-12-04 | Gruenenthal Gmbh | Derivados de 3-((hetero)aril)alquil-8-amino-2-oxo-1,3-diazaespiro-[4.5]-decano |
AR107354A1 (es) * | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
PL3402781T3 (pl) | 2016-01-13 | 2020-09-21 | Grünenthal GmbH | Pochodne 3-((hetero-)arylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu |
JP6854823B2 (ja) | 2016-01-13 | 2021-04-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 3−(カルボキシメチル)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体 |
TWI654181B (zh) | 2016-01-13 | 2019-03-21 | 歌林達有限公司 | 8-胺基-2-側氧基-1,3-二氮-螺-[4.5]-癸烷衍生物 |
JP6919977B2 (ja) | 2016-03-16 | 2021-08-18 | クラ オンコロジー,インク. | メニン−mllの置換された阻害剤及びその使用方法 |
KR102457933B1 (ko) | 2016-05-27 | 2022-10-24 | 브리스톨-마이어스 스큅 컴퍼니 | Rock의 억제제로서의 트리아졸론 및 테트라졸론 |
US10696674B2 (en) | 2016-07-07 | 2020-06-30 | Bristol-Myers Squibb Company | Spirolactams as inhibitors of ROCK |
WO2018009627A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
ES2814325T3 (es) | 2016-07-07 | 2021-03-26 | Bristol Myers Squibb Co | Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK |
US10654860B2 (en) | 2016-11-30 | 2020-05-19 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
TW201908293A (zh) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
EP3652164B1 (en) | 2017-07-12 | 2023-06-21 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
CN110869361B (zh) * | 2017-07-12 | 2023-06-02 | 百时美施贵宝公司 | 用于治疗心力衰竭的rock的五元氨基杂环和5,6元或6,6元双环氨基杂环抑制剂 |
CN110914257B (zh) * | 2017-07-12 | 2023-05-26 | 百时美施贵宝公司 | 作为rock抑制剂的螺庚基乙内酰脲 |
US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
CN111278825B (zh) | 2017-11-03 | 2023-05-02 | 百时美施贵宝公司 | 二氮杂螺rock抑制剂 |
KR20210003166A (ko) * | 2018-04-17 | 2021-01-11 | 템페스트 테라퓨틱스, 인크. | 비시클릭 카르복스아미드 및 그의 사용 방법 |
WO2024013736A1 (en) * | 2022-07-12 | 2024-01-18 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2653424A1 (en) * | 2006-06-08 | 2007-12-13 | Ube Industries, Ltd. | Novel indazole derivative having spiro ring structure in side chain |
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
MY155009A (en) * | 2006-12-27 | 2015-08-28 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
KR20100103646A (ko) * | 2007-12-26 | 2010-09-27 | 사노피-아벤티스 | 6치환된1(2h)이소퀴놀리논의 제조 방법 |
UY33726A (es) | 2010-11-15 | 2012-06-29 | Abbott Lab | Inhibidores de nampt y rock |
ES2684776T3 (es) | 2013-01-18 | 2018-10-04 | Bristol-Myers Squibb Company | Ftalazinonas e isoquinolinonas como inhibidores de ROCK |
TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物 |
EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
US9663529B2 (en) | 2013-07-02 | 2017-05-30 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
JP6434968B2 (ja) | 2013-07-02 | 2018-12-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての三環式ピリド−カルボキサミド誘導体 |
US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
CN107108581B (zh) | 2014-08-21 | 2020-06-23 | 百时美施贵宝公司 | 作为强效rock抑制剂的回接苯甲酰胺衍生物 |
US10123993B2 (en) | 2015-01-09 | 2018-11-13 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
AR107354A1 (es) * | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
KR102457933B1 (ko) | 2016-05-27 | 2022-10-24 | 브리스톨-마이어스 스큅 컴퍼니 | Rock의 억제제로서의 트리아졸론 및 테트라졸론 |
WO2018009627A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
US10696674B2 (en) | 2016-07-07 | 2020-06-30 | Bristol-Myers Squibb Company | Spirolactams as inhibitors of ROCK |
ES2814325T3 (es) | 2016-07-07 | 2021-03-26 | Bristol Myers Squibb Co | Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK |
US10654860B2 (en) | 2016-11-30 | 2020-05-19 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
-
2017
- 2017-01-12 AR ARP170100088A patent/AR107354A1/es unknown
- 2017-01-12 UY UY0001037073A patent/UY37073A/es unknown
- 2017-01-12 TW TW106101072A patent/TWI730032B/zh active
- 2017-01-13 PT PT177017852T patent/PT3402790T/pt unknown
- 2017-01-13 ES ES17701785T patent/ES2898698T3/es active Active
- 2017-01-13 CN CN201780015453.3A patent/CN108699038B/zh active Active
- 2017-01-13 KR KR1020187022838A patent/KR20180097749A/ko not_active Application Discontinuation
- 2017-01-13 EP EP17701785.2A patent/EP3402790B1/en active Active
- 2017-01-13 MA MA055633A patent/MA55633A/fr unknown
- 2017-01-13 WO PCT/US2017/013323 patent/WO2017123860A1/en active Application Filing
- 2017-01-13 EA EA201891557A patent/EA036172B1/ru not_active IP Right Cessation
- 2017-01-13 PL PL17701785T patent/PL3402790T3/pl unknown
- 2017-01-13 LT LTEPPCT/US2017/013323T patent/LT3402790T/lt unknown
- 2017-01-13 EP EP21193297.5A patent/EP3954681A1/en active Pending
- 2017-01-13 JP JP2018536481A patent/JP6976953B2/ja active Active
- 2017-01-13 RS RS20211514A patent/RS62690B1/sr unknown
- 2017-01-13 SI SI201730984T patent/SI3402790T1/sl unknown
- 2017-01-13 AU AU2017206820A patent/AU2017206820B2/en active Active
- 2017-01-13 MX MX2018008219A patent/MX2018008219A/es unknown
- 2017-01-13 US US16/067,619 patent/US10611776B2/en active Active
- 2017-01-13 HU HUE17701785A patent/HUE057455T2/hu unknown
- 2017-01-13 CA CA3010900A patent/CA3010900A1/en active Pending
- 2017-01-13 HR HRP20211888TT patent/HRP20211888T1/hr unknown
- 2017-01-13 SG SG11201805927YA patent/SG11201805927YA/en unknown
- 2017-01-13 BR BR112018013780-4A patent/BR112018013780B1/pt active IP Right Grant
- 2017-01-13 MA MA043862A patent/MA43862A/fr unknown
-
2018
- 2018-07-02 MX MX2021005311A patent/MX2021005311A/es unknown
- 2018-07-05 IL IL260448A patent/IL260448B/en active IP Right Grant
- 2018-07-12 CL CL2018001899A patent/CL2018001899A1/es unknown
- 2018-08-01 CO CONC2018/0008173A patent/CO2018008173A2/es unknown
-
2020
- 2020-01-10 US US16/739,363 patent/US10829501B2/en active Active
-
2021
- 2021-08-26 AU AU2021221872A patent/AU2021221872A1/en not_active Abandoned
- 2021-11-10 JP JP2021182946A patent/JP7268116B2/ja active Active
- 2021-12-09 CY CY20211101084T patent/CY1124858T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018008173A2 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
CO2017001152A2 (es) | Espirocicloheptanos como inhibidores de la cinasa rho (rock) | |
AR103895A1 (es) | Lactamas como inhibidores de rock | |
CO2017003833A2 (es) | Pirimidinonas como inhibidores del factor xia | |
UY35971A (es) | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia | |
CO2019014455A2 (es) | Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock | |
EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
CU20160167A7 (es) | Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias | |
EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
EA201891501A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
UY34959A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
EA201691442A1 (ru) | N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2 | |
NI201700029A (es) | Compuestos y composiciones como inhibidores de quinasa raf. | |
EA201691512A1 (ru) | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 | |
EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы |